🔗 Share this article

As the US undertakes sweeping adjustments to its vaccination schedules, one figure has surfaced somewhat surprisingly: Dr. Tracy Beth Høeg, a Danish American sports medicine doctor and epidemiologist who initially gained attention by expressing skepticism about coronavirus vaccines in the pandemic and has concentrated on potential deaths after Covid vaccination in her short tenure at the US Food and Drug Administration (FDA).

Planned Changes to Pediatric Vaccine Program

Health officials had intended to reveal radical revisions to the childhood vaccination calendar earlier this month, aligning the US with the Danish vaccine program, according to reports – a substantial departure that would place the US out of alignment with a large portion of the world with no evidence for benefit. The announcement has been delayed until the coming year.

Rather than Vinay Prasad, Dr. Høeg is scheduled to present at the event. She was newly appointed temporary leader of the FDA’s CDER, the fifth person to run the office this calendar year.

A Shift at the Agency

This interim role could signify a closer partnership between the drug and vaccine centers as Dr. Høeg and Prasad strengthen their influence at the agency – and it suggests a increased emphasis upon rolling back previously authorized immunizations at the FDA.

Høeg has often pushed for discontinuing some childhood immunization guidelines in the US to become more in line with Denmark, a nation with universal health coverage and a number of inhabitants about the size of Wisconsin’s.

So far public appearances, she has continued to focus on vaccines – typically the purview of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of pharmaceutical oversight.

Doubts Over Background

The appointee has little discernible background in drug development, oversight or leadership, which has been customary for former directors of the Center for Biologics Evaluation and Research. She has worked at the FDA as a key advisor to the FDA chief and the vaccine center since March.

“It seems she lacks to have any of the qualifications” for overseeing the drug-regulation department, said Jonathan Howard. “She has not conducted a clinical trial. She is not versed in managing a large organization. She has no expertise in industry regulation.”

Past directors of the center would “understand laws and regulations and the underlying principles of drug development”, noted Dr. Janet Woodcock. “Objectively, she has not acquired the type of experience that prior appointees who led CBER have had.”

CDER has an vast range of responsibilities at the FDA, she pointed out.

“The public just focuses on the innovative therapies, but the off-patent medication office authorizes a multitude of off-brand pharmaceuticals. There is also a biosimilars division, over-the-counter program and so forth, and every single one must be managed,” she explained. “The thing you overlook, that is the part that I always told people is going to bite you.”

Additionally, a major management component to the position, which oversees in excess of 5,000 staff members. “It’s a massive administrative position, if you execute it properly,” Woodcock added.

Response and Contentious Initiatives

In response to inquiries about Dr. Høeg's credentials and whether this selection signifies increased cooperation among agency officials on immunizations, a spokesperson stated that the “concerns are based on flawed presumptions”.

“Her resume is consistent with the functions of her position,” the official stated, noting the time Dr. Høeg spent advising the FDA commissioner on “medication safety and regulatory science, including predictive safety algorithms and immunization monitoring”.

In her interim role, Høeg takes over the commissioner’s new priority voucher program, a disputed one-day medication authorization process that apparently concerned her predecessors. “How are these therapies being selected for this expedited pathway? Who takes the choices?” Howard questioned. “There is a lot of confidentiality occurring at the FDA right now.”

In general, he said, “the agency seems to be moving towards laxer rules of all drugs, aside from immunizations.”

Documented History on Immunizations

With vaccines, Dr. Høeg has a more documented, if troubling, past, critics observe. She published a study using non-validated crowd-sourced reports to determine the rate of heart inflammation after Covid vaccination. She counseled the state of Florida chief medical officer Joseph Ladapo, who allegedly have modified findings to imply Covid vaccinations are pose a greater threat than they are.

Part of her “policy goals” for the current federal leadership encompassed changing guidelines for recently developed shots and halting “unnecessary” immunizations, she stated post-election on a online show. At the agency, Høeg has according to sources suggested barring adolescent males from receiving COVID-19 vaccinations.

“She is an all-around dogmatist who begins with her beliefs and tailors the evidence to fit the data in a very deceptive, dishonest way,” Howard argued.

Taking Control and a “Campaign of Retribution”

Høeg became part of fellow contrarians, {like|